

Novel method for modification of vein surface by Fetuin A and its optical characterization



UNIVERSITY OF LATVIA
INSTITUTE OF ATOMIC PHYSICS AND SPECTROSCOPY



and its optical characterization

Mindaugas Tamošiūnas
Institute of Atomic Physics and Spectroscopy
University of Latvia, Rīga, Latvia
mindaugas.tamosiunas@lu.lv

Ankit Mazumdar
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS, Dresden, Germany
ankit.mazumdar@ikts.fraunhofer.de

Iryna Tepliakova
Institute of Atomic Physics and Spectroscopy
University of Latvia, Rīga, Latvia
iryana.tepliakova@lu.lv


Vanesa Lukinsone
Institute of Atomic Physics and Spectroscopy
University of Latvia, Rīga, Latvia
vanesa.lukinsone@lu.lv

Natalia Beshchasna
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS, Dresden, Germany
natalia.beshchasna@ikts.fraunhofer.de

Roman Viter
Institute of Atomic Physics and Spectroscopy
University of Latvia, Rīga, Latvia
roman.viter@lu.lv

The aim: in the present work, we report on modification of vein samples by Fetuin-A and application of optical methods (Raman spectroscopy, NIR-fluorescence, optical coherence tomography) for characterization of samples to detect the immobilized Fetuin-A

Methods: bovine jugular vein xenogenic material preparation and optical testing



Basic preparation of tissue patches

Removing excess of glutaraldehyde
- chemical treatment
- protein treatment

Treatment with Fetuin-A
- only Fetuin-A
- dopamine coating

Optical characterization of the samples:
- Raman & NIR fluorescence spectroscopy
- optical coherence tomography (OCT)

In vitro shear stress, biostability vs calcification conditions testing

In vitro biocompatibility and cell culture calcification testing

In vivo calcification studies

Medical device requirements-conformed & industry-oriented biomaterial development

Table 1. Sample preparation protocol

#	Sample type	Glutaraldehyde fixed	Chemical treatment	Protein treatment	Fetuin-A incubation	Treatment condition
1.	Control	Yes	-	-	-	Fat, connective, and muscle tissue surgical removal from a vein; Glutaraldehyde (0.625%) 21 days fixation at room temperature (RT)
2.	Control (reduced glutaraldehyde)	Yes	NaBH ₄	-	-	0.1M NaBH ₄ (pH 7.4, RT, 24 h)
3.		Yes	-	Glycine	-	0.1M Glycine (pH 4.5), 37°C, 48 h (or 4°C, 24 h)
4.		Yes	-	L-glutathione	-	10% Citric acid, RT, 30 min
5.		Yes	NaBH ₄	Glycine	-	0.1M Glycine (pH 4.5), 37°C, 48 h + 0.1M NaBH ₄ (pH 7.4, RT, 24 h)
6.		Yes	NaBH ₄	L-glutathione	-	10% Citric acid (30 min, RT) + 0.1M NaBH ₄ (pH 7.4, RT, 24 h)
7.	Fetuin-A only	Yes	-	-	Yes	Incubated in 0.5 mg/ml Fetuin-A solution in NaHCO ₃ (RT, 24 h) on a rotator (120 rpm) above-stated
8.	Control (reduced glutaraldehyde), with Fetuin-A	Yes	-	Glycine	Yes	above-stated
9.		Yes	-	L-glutathione	Yes	above-stated
10.		Yes	NaBH ₄	-	Yes	above-stated
11.		Yes	NaBH ₄	Glycine	Yes	above-stated
12.		Yes	NaBH ₄	L-glutathione	Yes	above-stated
13.	Dopamine coated	Yes	C ₆ H ₁₁ NO ₂	-	-	2 mg/ml Dopamine in 0.1 M Tris (pH 8.5), above-stated
14.	Dopamine coated, with Fetuin A	Yes	C ₆ H ₁₁ NO ₂	-	Yes	above-stated

Table 2. Assignment of functionalization impact on Raman spectral bands in vein samples

Wavenumber (cm ⁻¹)	Mode assignment	Compound assignment	Dopamine treatment vs control	Fetuin-A treatment vs control	Dopamine & Fetuin-A vs. dopamine (only)
786	$\nu_{\text{sym}}(\text{O-P-O})$, U, T, C	DNA, nucleic acids, aromatic rings, vibrations in polydopamine, glutaraldehyde, out-of-plane ring breathing in polydopamine	↑	NS	NS
805	δ C-H (-CHO)	glutaraldehyde, out-of-plane ring breathing in polydopamine	↑	NS	NS
815	$\nu_{\text{sym}}(\text{O-P-O})$, RNA phosphate backbone, ring br. Tyr	RNA, Proteins	↑	↑	↓
903, 909	δ C-H (-CHO)	glutaraldehyde	↑	NS	NS
1031	$\nu(\text{C-O-C-O})$, $\nu(\text{C-O})$	GA- protein crosslinking, glutaraldehyde, nucleic acids	↓	NS	↓
1099	$\nu(\text{PO}_2^-)$	proteins	↑	NS	NS
1175	C-H in -plane bend, Tyr & Phe	nucleic acids	NS	↑	NS
1224, 1292	C, G amide III $\nu(\text{C-N})$ -H bend, $\nu_{\text{sym}}(\text{PO}_2^-)$	proteins, nucleic acids	↑	↑	NS
1448	CH_2 bend, $\delta\text{C-H}(-\text{CH}_2)$, $\nu\text{C=C}$	Proteins, glutaraldehyde	↓	↑	NS
1528	$\nu\text{C=C}$	imide ring of polydopamine	↑	NS	NS
1656	$\nu(\text{C=C})$, amide I $\nu(\text{C=O})$, $\nu(\text{C-N})$, N-H bend	lipids, proteins	NS	↑	NS
1946, 1979	carbonyl stretching	stretching vibrations in Fetuin-A conjugated with polydopamine; vibrations in extended π -systems, due to interaction between polydopamine's aromatic rings and Fetuin-A	↑	NS	↑
2178	ν C=N, ν C=C	oxidation and polymerization of dopamine into polydopamine	↑	NS	NS
2847	ν C-H	conjugation induced CH_2 symmetric stretching loss	NS	↑	NS
2880	$\nu_{\text{sym}} \text{C-H}(-\text{CH}_2)$	glutaraldehyde/fetuin-A cross-linking lead to more effective Raman scattering	↓	↑	NS
2939	ν (C-H)	glutaraldehyde	↓	NS	↓
3279	ν O-H	glutaraldehyde	↑	NS	NS

Results




Fig. 1 Immobilization of Fetuin-A on vein tissue patches was carried out using two approaches: (i) by incubating the patches in a Fetuin-A solution, and (ii) by pre-treating the patches with dopamine; the latter demonstrated enhanced binding affinity/interaction of Fetuin-A to bioprosthetic material




Fig. 2 Excess of glutaraldehyde was removed through protein treatment and/or chemical treatment with NaBH₄, which led to a reduction in Fetuin-A binding affinity to the inner surface of the veins. The Raman spectra have been normalized by area under the curve




Fig.3 Principal component analysis of statistical parameters derived from OCT in Fetuin-A immobilized vs control vein patches




Fig.4 Analysis of NIR-fluorescence intensity data from the samples

Conclusion: different strategies to immobilize Fetuin-A onto elastin-rich tissue patches were optically evaluated *in vitro*, and the optimal method (applying polydopamine coating before Fetuin-A functionalization) was identified for subsequent anticalcification properties testing

Acknowledgement: M-Era-Net project "Anti-calcification treatment of elastin-rich bioprosthetic materials using Fetuin A for aortic valved conduits" (VENUS), ES RTD/2022/21

